Evidence map›Paper›PMID 42321191›Full record

ArticleNature communications2026

Recurrent intra-tumour heterogeneity is a hallmark of metastatic prostate cancer.

Sirui Weng, Lachlan Cain, James Comben, Yangyi Zhang, Timothy Semple, Sara Alaei, David Yoannidis, Luciano Martelotto, Catherine Mitchell, Anupama Pasam and 22 more

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors.

Sirui WengPeter MacCallum Cancer Centre, Melbourne, VIC, Australia.ORCID 0000-0002-9130-8689
Lachlan CainPeter MacCallum Cancer Centre, Melbourne, VIC, Australia.
James CombenPeter MacCallum Cancer Centre, Melbourne, VIC, Australia.ORCID 0000-0002-5108-115X
Yangyi ZhangSt. Vincent's Institute of Medical Research, Fitzroy, VIC, Australia.
Timothy SemplePeter MacCallum Cancer Centre, Melbourne, VIC, Australia.ORCID 0000-0002-4048-1553
Sara AlaeiPeter MacCallum Cancer Centre, Melbourne, VIC, Australia.
David YoannidisPeter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Luciano MartelottoAdelaide Centre for Epigenetics, The University of Adelaide, Adelaide, SA, Australia.ORCID 0000-0002-9625-1183
Catherine MitchellPeter MacCallum Cancer Centre, Melbourne, VIC, Australia.ORCID 0000-0001-5596-9511
Anupama PasamPeter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Richard J YoungPeter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Benjamin BlythPeter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Joy HendleyPeter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Yuzhou FengPeter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Heather ThornePeter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Roslyn WallacePeter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Joanna ChanPeter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Julia ComoDepartment of Clinical Pathology, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Melbourne, VIC, Australia.
Lisa DevereuxPeter MacCallum Cancer Centre, Melbourne, VIC, Australia.ORCID 0000-0003-2435-5888
Himisha BeltranDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.ORCID 0000-0003-3259-2226
Daniel WetterskogUniversity College London Cancer Institute, London, UK.ORCID 0000-0003-4163-6438
Scott WilliamsPeter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Anthony T PapenfussThe Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.ORCID 0000-0002-1102-8506
Belinda ParkerPeter MacCallum Cancer Centre, Melbourne, VIC, Australia.ORCID 0000-0002-8333-1926
Paul NeesonPeter MacCallum Cancer Centre, Melbourne, VIC, Australia.ORCID 0000-0002-2729-5887
Gerhardt AttardUniversity College London Cancer Institute, London, UK.ORCID 0000-0002-4811-7983
David QuigleyDepartment of Urology, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0002-4726-1473
David L GoodePeter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Richard B PearsonPeter MacCallum Cancer Centre, Melbourne, VIC, Australia.ORCID 0000-0001-5919-5090
Luc FuricPeter MacCallum Cancer Centre, Melbourne, VIC, Australia.ORCID 0000-0002-1893-9812
Anna S Trigos *Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. Anna.Trigos@petermac.org.ORCID 0000-0002-5915-2952
Shahneen Sandhu *Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. Shahneen.Sandhu@petermac.org.ORCID 0000-0002-8660-4475

Funding

Department of Health | National Health and Medical Research Council (NHMRC) 2003115Department of Health | National Health and Medical Research Council (NHMRC) 2010070Department of Health | National Health and Medical Research Council (NHMRC) 2020149Prostate Cancer Foundation (PCF) Tactical AwardU.S. Department of Defense (United States Department of Defense) W81XWH-21-1-0638
6 · The paper itself

Abstract

The evolution to metastatic disease is a major determinant of cancer mortality. Cancer evolution involves a complex interplay between intrinsic genetics and transcriptional alterations and the microenvironment. To define mechanisms underpinning metastatic heterogeneity in late-stage disease, we focus on metastatic castration-resistant prostate cancer and employed single-cell multi-omics and whole-genome sequencing to deeply profile 34 metastatic lesions obtained from 9 patients through rapid autopsy. We find evolutionary convergence of intra-tumour heterogeneity, characterised by recurrent tumour populations acting as critical functional components of the tumour ecosystem, irrespective of clonal and microenvironmental backgrounds. We find little evidence of the microenvironment driving transcriptional heterogeneity, but there are signatures of co-adaptation between the microenvironment and tumour cells. In contrast, clonal evolution primarily foster widespread transcriptional changes that did not result in de novo functional states. Intra-patient functional convergence of tumour ecosystems across metastases indicates system-level selection pressures that drive the heterogeneity landscape of metastatic castration-resistant prostate cancer. Our findings reveal functional evolutionary convergence of metastatic disease into distinct intra-tumour subpopulations, identifying critical determinants for therapeutic targeting.

Indexed as

Genetic HeterogeneityNeoplasm Recurrence, LocalProstatic NeoplasmsProstatic Neoplasms, Castration-ResistantClonal EvolutionGene Expression Regulation, NeoplasticHumansMaleNeoplasm MetastasisSingle-Cell AnalysisTumor MicroenvironmentWhole Genome Sequencing

Identifiers

PMID42321191
PMCPMC13434311

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.